# PF-06651600 for the Treatment of Alopecia Areata

> **NCT03732807** · PHASE2,PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 718 (actual)

## Conditions studied

- Alopecia Areata

## Interventions

- **DRUG:** PF-06651600 Induction Dose
- **DRUG:** PF-06651600 Maintenance Dose #1
- **DRUG:** PF-06651600 Maintenance Dose #2
- **DRUG:** PF-06651600 Maintenance Dose #3
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03732807
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-03
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-06-24
- **Target enrollment:** 718 (ACTUAL)
- **Last updated:** 2022-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03732807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03732807, "PF-06651600 for the Treatment of Alopecia Areata". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03732807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*